Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA.
Genomics and Computational Biology, Teva Pharmaceutical Industries Ltd, West Chester, PA, USA.
Sci Rep. 2023 Oct 4;13(1):16699. doi: 10.1038/s41598-023-42431-4.
Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare and devastating childhood-onset lysosomal storage disease caused by complete loss of function of the lysosomal hydrolase α-N-acetylglucosaminidase. The lack of functional enzyme in MPS IIIB patients leads to the progressive accumulation of heparan sulfate throughout the body and triggers a cascade of neuroinflammatory and other biochemical processes ultimately resulting in severe mental impairment and early death in adolescence or young adulthood. The low prevalence and severity of the disease has necessitated the use of animal models to improve our knowledge of the pathophysiology and for the development of therapeutic treatments. In this study, we took a systematic approach to characterizing a classical mouse model of MPS IIIB. Using a series of histological, biochemical, proteomic and behavioral assays, we tested MPS IIIB mice at two stages: during the pre-symptomatic and early symptomatic phases of disease development, in order to validate previously described phenotypes, explore new mechanisms of disease pathology and uncover biomarkers for MPS IIIB. Along with previous findings, this study helps provide a deeper understanding of the pathology landscape of this rare disease with high unmet medical need and serves as an important resource to the scientific community.
黏多糖贮积症 IIIB 型(MPS IIIB)是一种罕见且具有破坏性的儿童发病的溶酶体贮积病,由溶酶体水解酶α-N-乙酰氨基葡萄糖苷酶完全丧失功能引起。MPS IIIB 患者缺乏功能性酶,导致硫酸乙酰肝素在全身的进行性积累,并引发一连串的神经炎症和其他生化过程,最终导致严重的智力障碍和青少年或成年早期的早逝。由于这种疾病的发病率低且病情严重,因此需要使用动物模型来提高我们对病理生理学的认识,并开发治疗方法。在这项研究中,我们采用系统的方法对经典的 MPS IIIB 小鼠模型进行了特征描述。我们使用一系列组织学、生化、蛋白质组学和行为学检测,在疾病发展的无症状前和早期症状阶段对 MPS IIIB 小鼠进行了测试,以验证先前描述的表型,探索疾病病理的新机制,并发现 MPS IIIB 的生物标志物。结合以前的发现,这项研究有助于更深入地了解这种具有高度未满足医疗需求的罕见疾病的病理全景,并为科学界提供了一个重要的资源。